TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
Standard
TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients. / Mahner, Sven; Wölber, Linn; Zu Eulenburg, Christine Gräfin; Schwarz, Jörg; Carney, Walter; Jänicke, Fritz; Milde-Langosch, Karin; Müller, Volkmar.
in: BMC CANCER, Jahrgang 10, 2010, S. 139.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - TIMP-1 and VEGF-165 serum concentration during first-line therapy of ovarian cancer patients.
AU - Mahner, Sven
AU - Wölber, Linn
AU - Zu Eulenburg, Christine Gräfin
AU - Schwarz, Jörg
AU - Carney, Walter
AU - Jänicke, Fritz
AU - Milde-Langosch, Karin
AU - Müller, Volkmar
PY - 2010
Y1 - 2010
N2 - Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.
AB - Angiogenesis appears to play an important role in ovarian cancer. Vascular endothelial growth factor (VEGF) has recently been implicated as a therapeutic target in ovarian cancer. The tissue inhibitor of metalloproteinase 1 (TIMP-1) is involved in tissue invasion and angiogenesis. The application of serum TIMP-1 and VEGF to monitor primary therapy and predict clinical outcome of patients with ovarian cancer is unclear.
U2 - 10.1186/1471-2407-10-139
DO - 10.1186/1471-2407-10-139
M3 - SCORING: Zeitschriftenaufsatz
VL - 10
SP - 139
JO - BMC CANCER
JF - BMC CANCER
SN - 1471-2407
ER -